Table 4.

Univariate and multivariate analyses for progression‐free survival

Variable	Univariate analysis			Multivariate analysis
	HR	95% CI	P	HR	95% CI	P
Age
≥70 vs. <70 years	1.19	0.77–1.84	0.420
Stage at diagnosis
Metastatic disease vs. locally advanced	1.88	1.22–2.90	0.004	1.84	1.11–3.04	0.017
Diabetes
Yes vs. no	0.98	0.62–1.56	0.961
ECOG PS
≥1 vs. 0	1.40	0.89–2.22	0.143
BMI
>25 vs. 18.5–25 kg/m2	0.84	0.53–1.32	0.460
Site of primary tumour
Body–tail vs. head	1.06	0.69–1.63	0.762
Δ SMI
≥10% vs. <10%	1.82	1.06–3.13	0.029	2.31	1.30–4.09	0.004
Visceral fat
≥44 vs. <44 cm3/h2	2.45	1.34–4.49	0.003	2.98	1.41–6.28	0.004
Δ Karnofsky PS
≥20% vs. <20%	1.97	1.08–3.60	0.027	1.43	0.63–3.23	0.383
Nutritional assessment
Yes vs. no	0.77	0.48–1.24	0.294
Nutritional supplementation
Yes vs. no	1.06	0.68–1.63	0.791
Δ Body weight
≥10% vs. <10%	2.60	1.03–6.59	0.043

The bold values are variables statistically significant in univariate and multivariate analysis.

Δ, from baseline to first radiological assessment; ECOG, Eastern Cooperative Oncology Group.